JP2022547313A5 - - Google Patents

Info

Publication number
JP2022547313A5
JP2022547313A5 JP2022515906A JP2022515906A JP2022547313A5 JP 2022547313 A5 JP2022547313 A5 JP 2022547313A5 JP 2022515906 A JP2022515906 A JP 2022515906A JP 2022515906 A JP2022515906 A JP 2022515906A JP 2022547313 A5 JP2022547313 A5 JP 2022547313A5
Authority
JP
Japan
Prior art keywords
hcmv
sequence
immunogenic composition
seq
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022515906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547313A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050392 external-priority patent/WO2021050864A1/en
Publication of JP2022547313A publication Critical patent/JP2022547313A/ja
Publication of JP2022547313A5 publication Critical patent/JP2022547313A5/ja
Withdrawn legal-status Critical Current

Links

JP2022515906A 2019-09-11 2020-09-11 ヒトサイトメガロウイルスワクチン Withdrawn JP2022547313A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962899129P 2019-09-11 2019-09-11
US62/899,129 2019-09-11
US201962899624P 2019-09-12 2019-09-12
US62/899,624 2019-09-12
US202062958623P 2020-01-08 2020-01-08
US62/958,623 2020-01-08
PCT/US2020/050392 WO2021050864A1 (en) 2019-09-11 2020-09-11 Human cytomegalovirus vaccine

Publications (2)

Publication Number Publication Date
JP2022547313A JP2022547313A (ja) 2022-11-11
JP2022547313A5 true JP2022547313A5 (OSRAM) 2023-09-20

Family

ID=74867306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515906A Withdrawn JP2022547313A (ja) 2019-09-11 2020-09-11 ヒトサイトメガロウイルスワクチン

Country Status (6)

Country Link
US (1) US20220347292A1 (OSRAM)
EP (1) EP4028030A4 (OSRAM)
JP (1) JP2022547313A (OSRAM)
AU (1) AU2020346041A1 (OSRAM)
CA (1) CA3154082A1 (OSRAM)
WO (1) WO2021050864A1 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
CN108430456B (zh) 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
JP6983455B2 (ja) 2016-09-14 2021-12-17 モデルナティーエックス， インコーポレイテッド 高純度ｒｎａ組成物及びその調製のための方法
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
JP2022521094A (ja) 2019-02-20 2022-04-05 モデルナティエックス インコーポレイテッド 共転写キャッピング用ｒｎａポリメラーゼバリアント
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN113521269A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
IL300739A (en) * 2020-08-25 2023-04-01 Modernatx Inc Human cytomegalovirus vaccine
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN115611757A (zh) * 2021-07-16 2023-01-17 江苏慧聚药业股份有限公司 mRNA传递剂的合成
CN115703713B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
AU2017345766A1 (en) * 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine

Similar Documents

Publication Publication Date Title
JP2019535665A5 (OSRAM)
EP4628510A1 (en) Multi-antigen chimeric poxvirus vaccine and use thereof
CN114854772B (zh) 水痘-带状疱疹病毒mRNA疫苗及其制备方法和应用
KR20110009249A (ko) 인간 파필로마 바이러스의 바이러스 유사 입자
JP2000516200A (ja) ウシの呼吸病に対するポリヌクレオチドワクチン処方
Tron et al. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences
CN110996999A (zh) 包含插入有脂肽的脂质体作为有效成分的疫苗佐剂及其用途
JP2002512026A5 (OSRAM)
CN116036259A (zh) 猴痘病毒多抗原mRNA疫苗及其应用
CN115820696A (zh) 治疗性多价HPV mRNA疫苗及其制备方法
CN113226364A (zh) 组合物和方法
US20250339511A1 (en) Nucleic acid vaccine against monkeypox virus and use thereof
WO2024041612A1 (zh) 一种正痘病毒属mRNA疫苗及其制备方法和用途
CN114277039B (zh) 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
WO2024188144A1 (zh) 痘病毒mRNA疫苗及用途
CN109219449B (zh) 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物
CN120202020A (zh) 工程化水痘带状疱疹病毒带状疱疹mRNA疫苗
CN116410992A (zh) 预防和/或治疗新型冠状病毒的mRNA、疫苗及其制备方法和应用
CN120888568A (zh) 一种预防或治疗乙肝病毒感染的mRNA疫苗及其应用
CN120305396A (zh) 一种猴痘病毒抗原表位mRNA组合物及其应用
AU2004281098B2 (en) Pharmaceutical compositions for therapeutic use
JP2002527527A (ja) 最小プロモーターおよびその使用
WO2025002352A1 (zh) 一种含有阳离子脂质的药物组合物及其用途
CN110237242B (zh) 促进毛发生长和/或再生的疫苗、其制备方法及其应用
HK40109231A (zh) Rna分子